Asep Medical’s sepsis diagnostic technology may improve odds of childhood appendicitis

VANCOUVER, British Columbia, February 27, 2024 /PRNewswire/ – Asep Medical Holdings Co., Ltd. (“Asep Co., Ltd.” or “company) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary sepsis gene expression signature can improve the assessment of appendicitis severity in children. Rob from Asep According to Dr. Stenstrom, medical director, “Abdominal pain is one of the most common complaints of children seen in the emergency room, so quickly and accurately distinguish between simple appendicitis and perforated appendicitis.” That is important.”

The association between appendicitis severity and sepsis was discovered as a result of a single-center prospective exploratory diagnostic clinical study published online. JAMA (Journal of the American Medical Association) Pediatrics In an article dated February 19, 2024 Gene expression profiling in pediatric appendicitis, Dhillon et al. Asep CEO Dr. Robert Hancock is the senior author.¹ Therefore, the gene expression signature underlying our AI-based sepsis diagnostic technology, called Sepset,^ERTMwe were able to differentiate between simple appendicitis (SA) and perforated appendicitis (PA), a more severe septic condition.

According to a related editorial by Maurizio Pacilli et al.², in the same issue, “The mortality risk for PA is 5%, whereas the mortality rate for SA is approximately 0.1%, highlighting the need for timely and accurate diagnosis and treatment…Dhillon aimed to identify blood-based biomarkers for use as clinical molecular diagnostics to differentiate between SA and PA in children. ” According to one study, the incidence of perforated appendicitis is³at least 19% in children undergoing appendectomy.

This clinical study asked, “What blood-based mechanistic changes differentiate pediatric patients with perforated appendicitis (PA) from those with simple appendicitis upon presentation to the emergency department?” Ta.

The study states, “A diagnostic study of 71 pediatric appendicitis patients using systems immunology techniques reveals a mechanistic understanding of a severe disease that exhibits immune dysregulation similar to that observed in sepsis. A blood-based gene expression signature of PA was also derived and was found to be potentially useful in the diagnosis of pediatric PA.Further research^Four sepset is^E.R. The gene signature was similarly diagnostic and, in fact, overlapped with the four gene signatures. ”

This study concluded that early diagnosis and management strategies for pediatric PA should be determined based on the underlying immune dysregulation and similarities with sepsis. Given that Asep is advancing preclinical development of an in vitro diagnostic test for sepsis gene expression, Sepset^E.R.In the future, this test may help diagnose the most severe forms of pediatric sepsis.

Dr. Robert EW Hancock, Founder, Chairman and CEO of Asep Medical, commented: “This research was conducted in Calgary in 2017, with final data analysis conducted in August 2023. Developed at UBC and currently using the following gene expression signature, this patented and was licensed to Sepset Biosciences, a subsidiary of Asep Medical, which allowed them to leverage this data to demonstrate the value of Sepset.^E.R. Techniques for identifying perforated appendicitis. Based on this new potential benefit of ER technology, we look forward to improving outcomes for children presenting with abdominal pain in the ER. ”

About ASEP Medical Holdings Co., Ltd.

Asep Medical Holdings Co., Ltd. (www.asepmedical.com) is dedicated to addressing the global problem of antibiotic failure by developing new solutions to important unmet medical needs in human medicine. The company is an amalgamation of three existing private companies, all with advanced development technology. Sepset Biosciences Inc. (proprietary diagnostic tools that enable early and timely identification of sepsis), ABT Innovations Inc. (broad-spectrum therapeutics to address multiple conditions – drug-resistant biofilm infections), SafeCoat Medical Inc. (antibacterial peptide medical device coating technology).

Cepcet Bioscience Co., Ltd.. (www.sepset.ca) is an in vitro diagnostic that includes patient gene expression signatures that can help assess the development of severe sepsis, one of the critical diseases that leads to antibiotic ineffectiveness, as antibiotics are the main initial therapeutic agent. The test is in the final stages of clinical research and preparation for commercialization. Treatment of sepsis. Sepsis was responsible for nearly 20% of all deaths on earth in 2017, and was responsible for virtually all deaths from COVID-19 and other pandemics. It has become. The SepsetER test is an easy-to-implement blood-based gene expression assay that provides results approximately one hour after a blood sample is collected in the emergency room or intensive care unit. This unique diagnostic technology is different from current diagnostic tests and enables risk assessment of progression to severe sepsis within approximately 60 minutes of testing. The gold standard, bacterial culture, provides results in about 15 hours, but can take up to three days. Asep Inc. believes its tests will reduce overall morbidity and mortality from sepsis by allowing physicians to make critical early decisions regarding appropriate treatment.

ABT Innovations Co., Ltd. (www.abtinnovations.ca) Peptide technology can be used to treat a wide range of bacterial biofilm infections (dental, wound, sinusitis, skin, medical device infections, chronic infections, pulmonary, bladder, ENT, orthopedics, etc.), anti-inflammatory drugs, etc. Covers the uses. , anti-infective immunomodulator and vaccine adjuvant. The company is in preclinical development with promising data for its first three indications.

SafeCoat Medical Inc. (www.safecoatmedical.com) technology involves antifouling self-assembling polymers combined with complex antimicrobial peptides, which can be applied to a variety of surfaces as antimicrobial and antifouling coatings. In particular, the present invention relates to coatings that can be applied to multiple medical devices and implants, and feasibility has been demonstrated in animal models. The company’s expertise also covers the manufacturing and application methods of these antimicrobial coatings.

Forward-looking statements —

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities laws. Forward-looking statements often include words such as “anticipates,” “plans,” “continues,” “anticipates,” “plans,” “intends,” “believes,” “predicts,” It is characterized by words such as “estimate” and “may”. “would,” “could,” “suggested,” “situated,” and other similar words, or that certain events or conditions “could” occur. or the statement “occurs”. These statements include, but are not limited to, the successful clinical trials of our sepsis in vitro diagnostic tests and our anticipated filing for regulatory market approval. our failure to obtain regulatory market approvals as planned or at all; We will begin preclinical research on our lead therapeutics with the hope that this will lead to rapid clinical trials. A specific period of sepsis with the company’s products. Potential opportunities to generate revenue. Therapeutic effects of the company’s products. and other statements regarding the Company’s proposed business plan. Throughout this news release, various assumptions are used in drawing the conclusions and making the predictions contained in the forward-looking statements. Forward-looking statements are based on management’s opinions and estimates at the time the statements are made and are subject to various risks, including the risk that the Company’s products may not perform as expected. the Company may not receive required regulatory market approvals or testing results; Our product testing may not be successful and market approval may not be obtained on time or at all. A company may not be able to generate revenue from its products as expected, or at all. The market for the Company’s products may not be as described in this news release. Asep Medical Inc.’s prospectus dated November 9, 2021, and various other risk factors identified in the company’s management’s discussion and analysis, can be found in the company profile below. www.sedar.com uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements; Asep Medical Inc. does not intend to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. We have no obligation to, and expressly disclaim.

Endnotes

View original content and download multimedia.https://www.prnewswire.com/news-releases/asep-medicals-sepsis-diagnostic-technology-can-provide-improved-odds-for-pediatric-appendicitis-302073431.html

SOURCE ASEP Medical Holdings Inc.

Company code: CNSX:ASEP, Frankfurt:JJ8, OTC-BB:SEPSF, OTC-PINK:SEPSF, OTC-QB:SEPSF